- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03024801
Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury
Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury: a Randomized, Controlled, Open-label Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent studies have shown that platelets, which contain a large number of cytokines and growth factors, can be beneficial in inflammatory response and postoperative bleeding, infection, bone formation, injury, muscle strain, and soft tissue healing. Platelets release a plethora of biologically active proteins to aggregate macrophages, mesenchymal stem cells (MSCs) and osteoblasts, thereby promoting degradation and clearing necrotic tissue, thus further activating wound healing. In fact, platelet-rich plasma (PRP) is now used clinically to promote cartilage repair.
By retrieving the Web of Science, a study by Havva et al. reported the clinical use of autologous PRP in 82 patients with advanced knee osteoarthritis with good outcomes. However, the clinical applications of this treatment have not been adequately investigated in randomized controlled trials. Given this, additional studies on the exact efficacy of this treatment are indispensible.
Three similar trial protocols to the current trial include 'Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma (NCT02365142)', 'PRP vs HA Intra-articular Knee Injections for Cartilage Defects (NCT02012530)', and 'Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee (MSCPRPOAK) (NCT01985633)'. In these trial protocols, knee injury extent and treatment success were assessed by Osteoarthritis Score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) score as outcome measures. However, there are several differences in the inclusion criteria and randomization of these trials in comparison with the current trial protocol.
Since autologous PRP predominantly functions to relieve pain and inhibit inflammatory responses, clinical injection of autologous PRP for cartilage injury can stimulate chondrocyte growth and matrix metabolism. Existing evidence has shown that autologous PRP can increase type II collagen production and reduce apoptosis in chondrocytes when combined with autologous bone marrow-MSCs. Furthermore, PRP can improve cartilage degeneration and inhibit the development of osteoarthritis (OA) when combined with hydrogel microspheres. Accordingly, the clinical use of autologous PRP can alleviate the symptoms of OA, promote recovery of motor function, and ultimately improve patient quality of life.
To date, the clinical use of low-dose autologous PRP has been reported to alleviate pain at the injury site in the treatment of articular cartilage injury, and achieve cartilage repair and proliferation by releasing growth factors that promote extracellular matrix synthesis and vascular reconstruction. However, the clinical applications of autologous PRP have not been systemically reported in randomized controlled clinical trials, leading to a lack of objective evidence on its effectiveness.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Knee cartilage injury
- Having normal and stable joint motion but no deformity
- Focal cartilage defects confirmed by magnetic resonance imaging (MRI), Outerbridge classification III/IV with a defect size < 10 cm2 graded as Outerbridge II at maximum
- Focal articular cartilage injury in the knee
- 14-55 years of age
- Provision of signed informed consent to participate in the trial
Exclusion Criteria:
- Poor general condition
- Blood diseases
- Use of local hormone treatment within 3 months before the trial
- Bleeding tendency
- Drug addiction, including anesthetic, alcohol and poison
- Inflammatory arthropathy, including specific and non-specific arthritis and severe osteoarthritis
- Contagious viral infection
- Metabolic diseases, such as gout and rheumatism
- Pregnant or lactating, or planning to become pregnant within 1 year after the initial registration
- Unable to cooperate with rehabilitation therapy because of psychological/mental disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: autologous platelet-rich plasma group
The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
|
The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
|
EXPERIMENTAL: normal saline group
The patients with knee cartilage injury were randomized to the normal saline group.
|
The patients with knee cartilage injury were randomized to the normal saline group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lysholm score
Time Frame: at 3 months after final injection
|
To assess functional recovery of the knee joint.
Lysholm score ranges from 0-100 with higher scores indicating better knee joint function.
A score <70 indicates damage to the knee joint function.
|
at 3 months after final injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2000 IKDC Subjective Knee Evaluation Form score
Time Frame: at 3 months after final injection
|
To used for assessing functional recovery of the knee joint.
Higher scores indicate better recovery.
|
at 3 months after final injection
|
Numerical rating scale score
Time Frame: changes of month 1, month 2 and month 3 after initial injection, and month 3 after final injection
|
To assess pain relief of the knee joint.
The numerical rating scale score ranges from 0-10, with a score of 0 indicating no pain and 10 indicating intense pain.
|
changes of month 1, month 2 and month 3 after initial injection, and month 3 after final injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Quanyi Guo, Ph.D, Chinese PLA Hospital, China
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ChinaPLAGH_003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cartilage Injury
-
Hyalex Orthopaedics, Inc.Recruiting
-
Keele UniversityRobert Jones and Agnes Hunt Orthopaedic and District NHS TrustCompletedCartilage Injury | Cartilage DamageUnited Kingdom
-
AlloSourceActive, not recruitingCartilage Injury | Cartilage DamageUnited States
-
AlloSourceTerminatedCartilage Injury | Cartilage DamageUnited States
-
Zimmer Orthobiologics, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
ISTO Technologies, Inc.TerminatedDefect of Articular Cartilage | Articular Cartilage Disorder | Degeneration; Articular Cartilage | Chronic Cartilage Injury | Acute Cartilage InjuryUnited States
-
Peking University Third HospitalRecruitingCartilage InjuryChina
-
Rush University Medical CenterJoint Restoration FoundationCompletedCartilage InjuryUnited States
-
TBF Genie TissulaireTerminated
-
Hadassah Medical OrganizationUnknown
Clinical Trials on autologous platelet-rich plasma
-
Rajavithi HospitalRecruitingAutologous Platelet-rich Plasma Supplement | Sperm Cryopreservation | Post-cryopreserved Sperm Quality | Semen AnalysisThailand
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingMenopause, Premature | Menopausal Syndrome | Premature Ovarian Failure | Ovarian Failure, Premature | Menopause Related ConditionsGreece
-
Assiut UniversityUnknownAutologous Platelet Rich Plasma Effect on Bone Healing
-
Mayo ClinicCompleted
-
Center for Vulvovaginal DisordersCompletedLichen Sclerosus
-
Matthew GettmanCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Santiste Medical Inc.Recruiting
-
University of Colorado, DenverCompletedPlatelet-Rich PlasmaUnited States
-
Genesis Athens ClinicNational and Kapodistrian University of AthensRecruitingInfertility, Female | Perimenopausal Disorder | Menstrual Cycle AbnormalGreece